Synthesis and biological evaluation of RGD-Conjugated MEK1/2 kinase inhibitors for integrin-targeted cancer therapy

Molecules

Volumn 18, Issue 11, 2013, Pages 13957-13978

  Li, Xiaoxiao ^a   Hou, Jianjun ^b   Wang, Chao ^b   Liu, Xinjie ^b   He, Hongyan ^b   Xu, Ping ^b   Yang, Zhenjun ^b   Chen, Zili ^a   Wu, Yun ^b   Zhang, Lihe ^b  

^a RENMIN UNIVERSITY OF CHINA   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Integrin v 3 receptor; MEK1 2 kinase inhibitor; PD0325901; RGD peptide; RGD MEKI conjugate; Tumor targeted drug delivery

Indexed keywords

ARGINYL-GLYCYL-ASPARTIC ACID; ARGINYLGLYCYLASPARTIC ACID; BENZAMIDE DERIVATIVE; DIPHENYLAMINE; DRUG DERIVATIVE; INTEGRIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; OLIGOPEPTIDE; PROTEIN KINASE INHIBITOR; VITRONECTIN RECEPTOR;

ARTICLE; CELL CYCLE; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; METABOLISM; TUMOR CELL LINE; WESTERN BLOTTING;

BENZAMIDES; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DIPHENYLAMINE; FLOW CYTOMETRY; HUMANS; INTEGRIN ALPHAVBETA3; INTEGRINS; MAP KINASE KINASE 1; MAP KINASE KINASE 2; OLIGOPEPTIDES; PROTEIN KINASE INHIBITORS;

EID: 84888609499     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules181113957     Document Type: Article

References (34)

1. McCubrey, J.A.; Steelman, L.S.; Chappell, W.H.; Abrams, S.L.; Wong, E.W.; Chang, F.; Lehmann, B.; Terrian, D.M.; Milella, M.; Tafuri, A.; et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochimi. Biophys. Acta 2007, 1773, 1263-1284.
2. Sebolt-Leopold, J.S.; Herrera, R.; Ohren, J.F. The mitogen-activated protein kinase pathway for molecular-targeted cancer treatment. Recent Results Canc. Res. 2007, 172, 155-167.
3. Cobb, M.H. MAP kinase pathways. Prog. Biophys. Mol. Biol. 1999, 71, 479-500.
4. Kolch, W. Meaningful relationships: The regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem. J. 2000, 351, 289-305.
5. Montagut, C.; Settleman, J. Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett. 2009, 283, 125-134.
6. Dhanasekaran, N.; Premkumar Reddy, E. Signaling by dual specificity kinases. Oncogene 1998, 17, 1447-1455.
7. Henderson, Y.C.; Chen, Y.; Frederick, M.J.; Lai, S.Y.; Clayman, G.L. MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo. Mol. Cancer Ther. 2010, 9, 1968-1976.
8. Haura, E.B.; Ricart, A.D.; Larson, T.G.; Stella, P.J.; Bazhenova, L.; Miller, V.A.; Cohen, R.B.; Eisenberg, P.D.; Selaru, P.; Wilner, K.D.; et al. A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin. Cancer Res. 2010, 16, 2450-2457.
9. LoRusso, P.A.; Krishnamurthi, S.S.; Rinehart, J.J.; Nabell, L.M.; Croghan, G.A.; Chapman, P.B.; Selaru, P.; Kim, S.; Ricart, A.D.; Wilner, K.D. Clinical aspects of a phase I study of PD-0325901, a selective oral MEK inhibitor, in patients with advanced cancer. Mol. Cancer Ther. 2007, 6, 3469S-3470S.
10. Majumdar, S.; Siahaan, T.J. Peptide-mediated targeted drug delivery. Med. Res. Rev. 2012, 32, 637-658.
11. Danhier, F.; Le Breton, A.; Preat, V. RGD-based strategies to target alpha (v) beta (3) integrin in cancer therapy and diagnosis. Mol. Pharm. 2012, 9, 2961-2973.
12. Juliano, R.L.; Ming, X.; Nakagawa, O.; Xu, R.; Yoo, H. Integrin targeted delivery of gene therapeutics. Theranostics 2011, 1, 211-219.
13. Ohren, J.F.; Chen, H.; Pavlovsky, A.; Whitehead, C.; Zhang, E.; Kuffa, P.; Yan, C.; McConnell, P.; Spessard, C.; Banotai, C.; et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat. Struct. Mol. Biol. 2004, 11, 1192-1197.
14. Wallace, M.B.; Adams, M.E.; Kanouni, T.; Mol, C.D.; Dougan, D.R.; Feher, V.A.; O'Connell, S.M.; Shi, L.; Halkowycz, P.; Dong, Q. Structure-based design and synthesis of pyrrole derivatives as MEK inhibitors. Bioorg. Med. Chem. Lett. 2010, 20, 4156-4158.
15. Barrett, S.D.; Bridges, A.J.; Dudley, D.T.; Saltiel, A.R.; Fergus, J.H.; Flamme, C.M.; Delaney, A.M.; Kaufman, M.; LePage, S.; Leopold, W.R.; et al. The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. Bioorg. Med. Chem. Lett. 2008, 18, 6501-6504.
16. Neustadt, B.R. Facile Preparation of N-(Sulfonyl)Carbamates. Tetrahedron Lett. 1994, 35, 379-380.
17. Li, X.F.; Atkinson, R.N.; King, S.B. Preparation and evaluation of new L-canavanine derivatives as nitric oxide synthase inhibitors. Tetrahedron 2001, 57, 6557-6565.
18. Vassis, S.; Karigiannis, G.; Balayiannis, G.; Militsopoulou, M.; Mamos, P.; Francis, G.W.; Papaioannou, D. Simple syntheses of N-alkylated spermidine fragments and analogues of the spermine alkaloid kukoamine A. Tetrahedron Lett. 2001, 42, 1579-1582.
19. Deutsch, H.M.; Glinski, J.A.; Hernandez, M.; Haugwitz, R.D.; Narayanan, V.L.; Suffness, M.; Zalkow, L.H. Synthesis of congeners and prodrugs .3. Water-soluble prodrugs of taxol with potent antitumor-activity. J. Med. Chem.1989, 32, 788-792.
20. Wu, Y.; Zhang, X.Z.; Xiong, Z.M.; Cheng, Z.; Fisher, D.R.; Liu, S.; Gambhir, S.S.; Chen, X.Y. microPET imaging of glioma integrin alpha(V)beta(3) expression using Cu-64-labeled tetrameric RGD peptide. J. Nucl. Med. 2005, 46, 1707-1718.
21. Wu, Y.; Cai, W.B.; Chen, X.Y. Near-infrared fluorescence imaging of tumor integrin alpha(v)beta(3) expression with Cy7-labeled RGD multimers. Mol. Imaging. Biol. 2006, 8, 226-236.
22. Zhang, X.Z.; Xiong, Z.M.; Wu, Y.; Cai, W.B.; Tseng, J.R.; Gambhir, S.S.; Chen, X.Y. Quantitative PET imaging of tumor integrin alpha(v)beta(3) expression with F-18-FRGD2. J. Nucl. Med. 2006, 47, 113-121.
23. Lorusso, P.M.; Adjei, A.A.; Varterasian, M.; Gadgeel, S.; Reid, J.; Mitchell, D.Y.; Hanson, L.; DeLuca, P.; Bruzek, L.; Piens, J.; et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J. Clin. Oncol. 2005, 23, 5281-5293.
24. Adjei, A.A.; Cohen, R.B.; Franklin, W.; Morris, C.; Wilson, D.; Molina, J.R.; Hanson, L.J.; Gore, L.; Chow, L.; Leong, S.; et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J. Clin. Oncol. 2008, 26, 2139-2146.
25. Elduque, X.; Sánchez, A.; Sharma, K.; Pedroso, E.; Grandas, A. Protected maleimide building blocks for the decoration of peptides,peptoids, and peptide nucleic acids. Bioconjugate Chem. 2013, 24, 832-839.
26. Aufort, M.; Gonera, M.; Lelait, M.A.; Czarny, B.; Clainche, L.L.; Thaï, R.; Landra, A.; Brimont, M.R.; Dugave, C. Synthesis, in vitro screening and in vivo evaluation of cyclic RGD analogs cyclizedthrough oxorhenium and oxotechnetium coordination. Eur. J. Med. Chem. 2011, 46, 1779-1788.
27. Zhu, H.; Wickenden, J.G.; Campbell, N.E.; Leung, J.C.T.; Johnson, K.M.; Sammis, G.M. Construction of carbo- and heterocycles using radical relay cyclizations initiated by alkoxy radicals. Org. Lett. 2009, 11, 2019-2022.
28. Ballini, R.; Petrini, M. A new procedure for dethioacetalization via equilibrium exchange with aqueous acetone, paraformaldehyde and amberlyst 15 as acidic catalyst. Synthesis 1990, 4, 336-337.
29. Chang, S.Y.; Bae, S.J.; Lee, M.Y.; Baek, S.H.; Chang, S.; Kim, S.H. Chemical affinity matrixbased identification of prohibitin as a binding protein to anti-resorptive sulfonyl amidine compounds. Bioorg. Med. Chem. Lett. 2011, 21, 727-729.
30. Ramalingam, K.; Raju, N. Heteroatom-Bearing Ligands and Metal Complexes Thereof. U.S. Patent 5608110, 1997.
31. Miao, Z.W.; Liu, J.J.; Thea, N.; Russell, D. Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides. WO 2006/069246, 2006.
32. Barrett, S.D.; Biwersi, C.M.; Chen, M.H.G.; Kaufman, M.D.; Tecle, H.; Warmus, J.S. Oxygenated Esters of 4-Lodo Phenylamino Benzhydroxamic Acids. U.S. Patent 2004/0054172A1, 2004.
33. Miao, Z.W.; Atkinson. K.C.; Biroc, S.; Buss, T.; Cook, M.; Krayonv, V.; Marsden, R.; Pinkstaff, J.; Skidmore, L.; Sun, Y.; Szydlik, A.; Valenta, I. Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acid Linked Dolastatin Derivatives. WO 2012/166560A1, 2012.
34. Wallace, E.; Hurley, B.; Yang, H.W.; Lyssikatos, J.; Blake, J.; Marlow, A.L. Heterocyclic Inhibitors of MEK and Methods of Use Thereof. U.S. Patent 2005/0054701A1, 2005.